U.S. Physical Therapy Stock Price and Value Analysis

U.S. Physical Therapy (NYSE:USPH) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold U.S. Physical Therapy to reach your target.

Target type

USPH Free Cash Flow Trend

Free Cash Flow trendline for USPH
Free Cash Flow trendline for U.S. Physical Therapy
CSV

Based on historical returns, we believe that U.S. Physical Therapy can grow its free cash at a rate of about 9%. That's positive!

AdvantagesDisadvantagesNeutral
  • This company is solid.
  • This company is making money at a decent rate.
  • This company has stable growth.
  • This company has an average dividend yield.
None.
  • This stock looks fairly priced.

Inside the USPH Numbers

USPH Price
(U.S. Physical Therapy stock price per share)
$95.93
[?] USPH Fair Price
(based on intrinsic value)
$96.93
[?] USPH Safety Price (based on a variable margin of safety) $63.00
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 636% higher than other Healthcare stocks
[?] PE Ratio versus Industry 169% higher than other Medical Care Facilities stocks
[?] Cash Yield 3.05%
[?] Free Cash Flow Jitter 20%
[?] Dividend Yield 1.94% (tax impact)
Shares Shorted 1,129,075

Insider Activity Summary

In the six months to 2026-11-21, 1 insider bought in 2 trades, about $49 thousand, and no insider sold shares.

The six months before that had 0 buys and 5 sales.

Recent Insider Activity

Open-market buys and sells reported by U.S. Physical Therapy's officers, directors, and 10% owners on SEC Form 4. Routine transactions (tax withholding, option exercises, and stock grants) are excluded -- these are discretionary trades only.

Date Insider Type Shares Price
2026-06-09 Minan Peter Francis Buy 288 $61.50
2026-06-08 Minan Peter Francis Buy 492 $63.14
2026-03-11 REEVE GRAHAM D. (COO) Sell 662 $78.86
2026-03-09 REEVE GRAHAM D. (COO) Sell 1 $78.52
2026-03-06 REEVE GRAHAM D. (COO) Sell 1,807 $82.25
2026-03-06 Binstein Richard (EVP Gen'l Counsel & Secretary) Sell 3,000 $81.64
2025-11-24 REEVE GRAHAM D. (COO) Sell 743 $71.01
2025-11-20 Gilmartin Kathleen A Buy 4,000 $69.00
2025-09-11 HAM NANCY Sell 600 $81.71
2025-09-05 Williams Eric Joseph (President and COO) Sell 1,000 $85.25

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 1,129,075 shares shorted. With 14,543,307 shares available for purchase and an average trading volume over the past 10 trading days of 240,430, it would take at least 4.7 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2009 885978 27.1
2010 885978 26.7
2011 885978 29.1
2012 885978 35.5
2013 885978 40.9
2014 885978 41
2015 885978 32.8
2016 885978 45.3
2017 885978 50.2
2018 885978 66.2
2019 885978 54.6
2020 885978 91.9
2021 885978 68.3
2022 885978 50.2
2023 885978 73.3
2024 885978 66.4
2025 885978 65.3

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 17 fiscal years from 2009 to 2025 with positive net income, operating cash flow totaled $971 million against net income of $444 million, or 2.19 times.

In 2025, operating cash flow was 1.90 times net income, compared with 1.95 times for the earliest three years (2009 to 2011).

In 2025, capital expenditures were $14.1 million, 18.7% of operating cash flow of $75.1 million, which leaves an estimated $61 million after capex. Across the 17 years with reported capex, it averaged 12.4% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2009 11.8 30.9 3.9 2.63
2010 15.6 30.5 3.7 1.95
2011 21 32.7 3.2 1.56
2012 17.9 39.2 4.2 2.19
2013 12.7 44.8 4.6 3.52
2014 19.1 45.2 5.2 2.36
2015 20.6 37.5 6.3 1.82
2016 20.6 51 8.3 2.48
2017 22.3 56.5 7.1 2.54
2018 34.9 73 7.2 2.09
2019 40 62.4 10.2 1.56
2020 35.2 100 7.6 2.84
2021 40.8 76.4 8.2 1.87
2022 32.2 58.5 8.2 1.82
2023 28.2 82 9.3 2.90
2024 31.4 74.9 9.2 2.38
2025 39.6 75.1 14.1 1.90

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 10 fiscal years from 2016 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $632 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In the 10 of those years with dividend payment facts, dividends paid totaled $167 million, 26.4% of the estimated free cash flow of those years. Estimated free cash flow was at least the dividends paid in 10 of those 10 years.

In 1 of the 10 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $5.6 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

In 2025, dividends and cash spent repurchasing shares together were $32.9 million, 50.5% of estimated free cash flow of $65.3 million.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2016 45.3 8.5 n/a 8.5 18.8%
2017 50.2 10.1 n/a 10.1 20.0%
2018 66.2 11.7 n/a 11.7 17.6%
2019 54.6 14.6 n/a 14.6 26.6%
2020 91.9 4.1 n/a 4.1 4.5%
2021 68.3 18.8 n/a 18.8 27.5%
2022 50.2 21.3 n/a 21.3 42.4%
2023 73.3 24.1 n/a 24.1 32.9%
2024 66.4 26.5 n/a 26.5 40.0%
2025 65.3 27.4 5.6 32.9 50.5%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $201 million in 2009 and $781 million in 2025, a compound annual growth rate of 8.8% over 16 years.

Revenue rose 16.3% from 2024 to 2025.

Our estimated free cash flow was $65.3 million in 2025, 8.4% of revenue. In 2009 the estimated margin was 13.4%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2009 201 27.1 13.4%
2010 211 26.7 12.7%
2011 232 29.1 12.6%
2012 250 35.5 14.2%
2013 264 40.9 15.5%
2014 305 41 13.4%
2015 331 32.8 9.9%
2016 357 45.3 12.7%
2017 414 50.2 12.1%
2018 454 66.2 14.6%
2019 482 54.6 11.3%
2020 423 91.9 21.7%
2021 495 68.3 13.8%
2022 553 50.2 9.1%
2023 605 73.3 12.1%
2024 671 66.4 9.9%
2025 781 65.3 8.4%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $35.6 million against total liabilities of $434 million, or 8.2% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 36.0% of total assets in 2025, compared with 17.4% in 2010, an increase of 18.7 percentage points.

Stockholders equity was $477 million in 2025, compared with $116 million in 2010, a rise of 309.8%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 6.3% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2010 141 9.2 24.5 116
2011 163 10 41.7 122
2012 172 11.7 37.1 135
2013 224 12.9 83.8 151
2014 245 14.3 83.2 167
2015 281 15.8 109 158
2016 351 20 163 189
2017 419 21.9 110 206
2018 443 23.4 92.3 217
2019 631 23.5 181 242
2020 594 32.9 184 278
2021 749 28.6 297 297
2022 858 31.6 374 317
2023 997 153 345 477
2024 1,167 41.4 408 490
2025 1,204 35.6 434 477

What the Price Implies

How to read this: discounted cash flow, intrinsic value.

At today's price of $95.93, our model's value equals that price if free cash flow grows an average of 9.3 percent a year over the 10 projection years. Our model assumes 9.5 percent a year for this stock, so the price implies growth of 9.3 percent, which is below the 9.5 percent our model assumes. This is the growth the price implies under our model, not a forecast of growth or a price target.

The table shows the same calculation at a price 20 percent lower and 20 percent higher than today's price, and the model's own growth rate at its fair price.

The model starts from the company's average free cash flow of $42.9 million, grows it over 10 years along the year-by-year growth path stored for this stock (the pace fades over the years, and the implied rate keeps that shape, so the rates here are 10-year averages), discounts it at 10.1 percent a year, adds a terminal value that grows 2.5 percent a year after year 10, adds the company's net worth, and divides by shares outstanding.

The baseline is the company's average free cash flow, and cyclical companies can mislead it.

CasePrice per shareAverage annual free cash flow growth
20 percent below the current price $76.74 4.4%
Current price $95.93 9.3%
20 percent above the current price $115.12 12.8%
Our model (stored fair price) $96.93 9.5%

Model assumptions: 10.1 percent discount rate, 2.5 percent terminal growth, 10 projection years. To try your own growth rate, use the intrinsic value calculator on this page. It uses a simpler single-rate model, so its results will not match the figures above exactly.

Price Versus Our Estimated Value

Free cash flow was positive in all 17 fiscal years we have for U.S. Physical Therapy under its current SEC filer.

U.S. Physical Therapy's average free cash flow rose sharply, from $27.6 million in its earliest three years to $68.3 million in its latest three.

Year-to-year variability in free cash flow is fairly steady, measured at 20%.

The price of $95.93 falls between the safe value ($63.00) and fair value ($96.93) for U.S. Physical Therapy.

The dividend yield for U.S. Physical Therapy is 1.94%.

These numbers change when new filings or prices arrive, so treat this page as a snapshot and check the company's own filings.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 636% above the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 169% above the average for stocks in the Medical Care Facilities industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Medical Care Facilities industry, the ones closest in market capitalization to U.S. Physical Therapy, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
U.S. Physical Therapy (USPH) 1,432 - 1.9% 3.0% 1% below
Healthcare Services Group (HCSG) 1,667 16.7 - 4.0% 17% below
Progyny (PGNY) 2,630 32.8 - - 409% above
Surgery Partners (SGRY) 3,505 - - - 105% above
DaVita (DVA) 10,129 12.2 - 15.2% 57% below
Universal Health Services (UHS) 10,345 7.5 0.5% 14.1% 71% below
Encompass Health Corporation (EHC) 13,114 21.4 0.6% - 438% above

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 885978.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: USPH annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in USPH

Does U.S. Physical Therapy have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: USPH

This example shows how we apply the Trendshare checklist to USPH: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 95.93
    • Market cap: $1.4B
    • EPS: -1.33
  2. Step 2 — Valuation checks

    • P/E: —
    • FCF yield: 3.0%
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.